SLBT Stock Forecast: SL Science Holding Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.54
−6.61% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 0 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$304.3M
Ticker Nerd rank
0/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−25.4%
1M
−63.8%
From high
−95.1%
From low
0.0%
$1
$11
Range since 9 June 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores SL Science Holding Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
0/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
20
Momentum
10
Value
9
Accruals
5
Growth
1
Quality
1
Issuance
0
Volatility
0

Revisions (20): Analysts have, on balance, been raising their forecasts.

Volatility (0): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SLBT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLBT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 9 June 2026Adjusted close, US dollars
$0$2$4$6$8$10Jul 26Aug 26Sep 26Oct 26Nov 26SLBT

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SLBT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SLBT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SLBT vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jul 26Aug 26Sep 26Oct 26Nov 26SLBTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLBT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
94.3×

Cheaper than 3% of US stocks

Price / book
0.4×

Cheaper than 88% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−7.6%

Higher than 18% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−70.6%

Higher than 16% of US stocks

Net margin
−72.5%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−167.2%

Higher than 9% of US stocks

Return on assets
−135.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SL Science Holding Ltd. has a market value of $304.3M.

  • Shares outstanding: 560.8M.

  • SL Science Holding Ltd. employs 14 people.

market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SLBT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLBTSL Science Holding Ltd.$304.3M0
PROKProKidney Corp.$313.9M17
AVIRAtea Pharmaceuticals, Inc.$317.6M81
SPRYARS Pharmaceuticals, Inc.$297.6M13
XFORX4 Pharmaceuticals, Inc.$297.4M65
CCCCC4 Therapeutics, Inc.$325.7M65
EVMNEvommune, Inc.$291.1M11

Take a look at SLBT’s peer groups, ranked by the model: consumer staples stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own SL Science Holding Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SLBT

How does Ticker Nerd's model rank SLBT?

As at 21 Nov 2026, SL Science Holding Ltd. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (20 of 100).

What is the SLBT stock forecast for 2030?

No analyst covering SL Science Holding Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLBT are extrapolating price history, which says nothing about the business.

What does SL Science Holding Ltd. do?

SL Science Holding Ltd. is a biomedical company focused on cell therapy, exosome products, and cellular and gene therapies. The company develops and commercializes proprietary platforms and related solutions across its main business segments, including Exosome products, CD-19 Armed-T products, and GDT cell therapy products.

Company

About SL Science Holding Ltd.

SL Science Holding Ltd. is a biomedical company focused on cell therapy, exosome products, and cellular and gene therapies. The company develops and commercializes proprietary platforms and related solutions across its main business segments, including Exosome products, CD-19 Armed-T products, and GDT cell therapy products. Its offerings include immune cell development services, skincare product formulations, and milk-derived exosome-based products, reflecting a combination of life sciences and applied biotechnology applications. Based in Taipei, Taiwan, SL Science Holding Ltd. serves the broader healthcare and biotechnology market by advancing technologies used in regenerative medicine, cancer-related research, and specialty bioactive products. The company positions its proprietary GDT platform and related technologies at the center of its current operations, supporting standardized and scalable approaches within the cell therapy field.

CEO Mr. Ching-Dong Wang · 14 employees · Taiwan · https://www.sl-bio.com